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Abstract
Human tumors using the alternative lengthening of telomeres (ALT) exert high rates of telomere dysfunction. Numer-
ical chromosomal aberrations are very frequent, and structural rearrangements are widely scattered among the
genome. This challenging context allows the study of telomere dysfunction–driven chromosomal instability in neo-
plasia (CIN) in a massive scale. We used molecular cytogenetics to achieve detailed karyotyping in 10 human ALT
neoplastic cell lines. We identified 518 clonal recombinant chromosomes affected by 649 structural rearrangements.
While all human chromosomes were involved in random or clonal, terminal, or pericentromeric rearrangements
and were capable to undergo telomere healing at broken ends, a differential recombinatorial propensity of specific
genomic regions was noted.We show that ALT cells undergo epigenetic modifications rendering polycentric chromo-
somes functionally monocentric, and because of increased terminal recombinogenicity, they generate clonal recom-
binant chromosomes with interstitial telomeric repeats. Losses of chromosomes 13, X, and 22, gains of 2, 3, 5, and
20, and translocation/deletion events involving several common chromosomal fragile sites (CFSs) were recurrent.
Long-term reconstitution of telomerase activity in ALT cells reduced significantly the rates of random ongoing telo-
meric and pericentromeric CIN. However, the contribution of CFS in overall CIN remained unaffected, suggesting
that in ALT cells whole-genome replication stress is not suppressed by telomerase activation. Our results provide
novel insights into ALT-driven CIN, unveiling in parallel specific genomic sites that may harbor genes critical for
ALT cancerous cell growth.
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Introduction
Mitotic chromosome integrity in humans relies on efficient DNA
damage responses (DDR), unfailing cell cycle checkpoints, as well as
functional telomeres and centromeres [1–4]. Centrosomes, kineto-
chores, chromatid cohesion, and nuclear and microtubule architecture
also play important roles in preserving faithful mitotic chromosome
segregation [5,6]. Chromosomal instability in neoplasia (CIN) is an
extremely aggravated form of ongoing mitotic infidelity that is observed
in most cancer cell populations [4]. Randomly dispersed CIN generates
clonal tumorigenic chromosome aberrations, contributes dramatically
to intratumor genomic heterogeneity, and is mainly responsible for
cancer genome evolution that shapes the multistep process of neoplasia
[3,7]. Even more, CIN is related to advanced, incurable malignancy
and is thought to complicate all current and future oncotherapeutic
strategies [4]. Understanding the patterns and driving mechanisms of
CIN may provide new tools toward personalized therapeutical schemes
that will be capable to defeat advanced cancers [8].
In every neoplastic cell division, stability of chromosome content
is challenged by inherent impaired DDR, oncogene-induced DNA
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replication stress, and telomere deprotection [9,10]. Replication stress
due to chemical agents, activated oncogenes, or genetic interventions
has been shown to cause random illegitimate recombinogenicity of
cancer chromosomes that occurs frequently at common chromosomal
fragile sites (CFSs) and can create novel clonal rearrangements [9–12].
CFSs are AT-rich chromosomal regions that preferentially form
cytologically visible gaps or breaks on metaphase chromosomes under
replication stress [13]. The DNA polymerase inhibitor aphidicolin
introduces replication stress and induces 77 of 88 known human CFSs
[13]. Fragile sites are conserved among mammals and are also found
in lower eukaryotes including yeast and flies [9]. CFSs are hotspots
for gene amplification and viral integration, and they have been also
implicated in sister chromatid exchanges and in the generation of
constitutional or acquired deletions and translocations [9].
Telomeres protect the ends of eukaryotic chromosomes [14]. In most
human somatic tissues, these specialized nucleoprotein complexes
are challenged after each round of DNA replication. From yeast to
humans, replicative loss of telomeric DNA is replenished by the action
of the RNP enzyme telomerase or by the telomerase-independent
alternative lengthening of telomeres (ALT) [15]. Most normal human
tissues do not possess a constitutive means to fully maintain their
telomeres; thus, actively dividing cells demonstrate progressive telomeric
loss and deprotection [14]. Critical impairment of telomere protection
activates DDR, and the cell cycle becomes arrested [16]. In normal cells,
senescence and apoptosis are biologic barriers that prevent neoplastic
transformation [1]. To overcome these barriers, human malignancies
sustain continuous cellular growth by activating telomerase [14,17] or
by using the alternative pathway of telomere lengthening (ALT) [15].
The ALT pathway for telomere elongation was originally described
in yeast and in mammalian immortalized and cancer cells lacking telo-
merase [15,18]. Although relatively rare in human neoplasia, the ALT
pathway has been frequently observed in various types of aggressive
human tumors such as osteosarcomas, undifferentiated pleomorphic
sarcomas, leiomyosarcomas, astrocytic tumors (grades 2 and 3), and
pancreatic neuroendocrine tumors [19]. In addition, the engagement of
the ALT pathway may confer acquired resistance to cancer therapy in
telomerase-positive cancer cells treated with telomerase inhibitors and
has been considered a major burden for current and future telomere-
based antitumor therapeutics [20].
Although not well understood, the mechanisms of ALT are thought
to engage non-homologous end joining (NHEJ) to seed “neo-telomeres”
at broken chromosome ends [21]. However, the extent of this pro-
cess still remains unknown [22]. ALT also implies the assembly and
activation of the complex homologous recombination-mediated DNA
replication machinery that elongates telomeres in the absence of telo-
merase [23]. Cells using the ALT pathway display extensive telomeric
length heterogeneity, ALT-associated promyelocytic leukemia (PML)
nuclear bodies (APBs), extrachromosomal telomeric C-circles, massive
telomere dysfunction, large-scale epigenetic modifications at chromo-
some termini, as well as high rates of structural and numerical chromo-
some instability [23].
Telomere dysfunction–driven genome damage is operated by fre-
quent chromosomal break-fusion-bridge (B/F/B) cycles [24,25]. The
B/F/B cycles can generate various types of oncogenic structural chromo-
some rearrangements and may lead to extensive loss of genomic material
through anaphase lagging of whole chromosomes or chromosomal seg-
ments [3,26]. In highly proliferating ALT cells, a continuous process
of frequent B/F/B cycles generates very complex karyotypes that up to
now have not been analyzed in detail [27]. Numerical chromosomal
aberrations are very frequent, whereas structural rearrangements affect
almost every single chromosome [24]. This extremely challenging con-
text provides excellent grounds for comparative analysis of clonal and
random chromosome anomalies and allows the study of processes
related to recombinant chromosome functionality in a large scale.
In several histopathologic types of malignancies, specific chromosomal
aberrations have been associated with biologic mechanisms, along with
the diagnosis or prognosis of the disease [28]. Little is known about
recurrent chromosome rearrangements that might characterize the ALT
pathway and may reflect known or unravel unknown genes or biologic
pathways operating in this type of malignancy [27,29]. Furthermore,
our knowledge on the distribution of CIN between different chromo-
somes of the human genome and the processes related to clonal per-
petuation of recombinant chromosomes in neoplasia still remains poor.
We combined multicolor fluorescence in situ hybridization (M-FISH),
inverted 4,6-diamidino-2-phenylindole (DAPI) banding, telomere- or
centromere-specific FISH, strand-specific chromatid orientation FISH
(CO-FISH), and immunocytochemistry to achieve detailed molecular
karyotyping in 10 human ALT cell lines. In a cohort of 649 unique
clonal structural aberrations, we present the frequencies and chromo-
somal locations of different types of structural rearrangements and
describe cytogenetic markers of ALT continuous growth. Our data
demonstrate that ALT-rearranged chromosomes are products of fre-
quent ongoing telomeric, pericentromeric, and CFS recombinogenicity,
and their clonality is preserved through extensive telomere healing and
by widespread centromere epigenetic modifications that allow polycen-
tric chromosomes to become functionally monocentric and perpetuate
in culture. However, beyond extreme complexity compelled by frequent
B/F/B cycles and despite the highly increased rates of pericentromeric
and CFS instability, human ALT-neoplastic karyotypes revealed recur-
rent numerical and structural chromosome anomalies that unravel
biologic pathways related to cancerous cellular growth.
Materials and Methods
Cell Lines and Culture Conditions
The osteosarcoma cell line Saos-2 was obtained from the American
Type Culture Collection (Wesel, Germany), and the osteosarcoma
cell line U2-OS was a gift from E. Gonos (National Hellenic Re-
search Foundation, Athens, Greece). The SV-40 large T-antigen trans-
formed ALT cell lines GM-847, VA-13, and IMR-90 were donated by
A. Londoño-Vallejo (Institute Curie, Paris, France) [30]. In addition,
we used a VA-13 derivative cell line that stably expresses human telo-
merase RNA component (hTERC) and human telomerase reverse tran-
scriptase (hTERT) and has reconstituted telomerase activity (VA-13TA)
as described by Ford et al. [31]. The VA-13+hTERC+hTERT (VA-
13TA) was a gift from J. W. Shay. The ALT liposarcoma Lisa-2 and
Ls-2 and the SV-40–transformed human ovarian surface epithelium cell
lines HIO107 and HIO118 were kindly provided by D. Broccoli (Fox
Chase Cancer Center, Philadelphia, PA) [32]. The T-24 bladder cancer
cells were provided by T. Vlahou (Biomedical Research Foundation of
the Academy of Athens, Athens, Greece). HeLa and breast cancer
MCF-7 cells were gifts from I. Irminger-Finger (GenevaMedical School,
Geneva, Switzerland). The colon cancer SW-480 cell line was obtained
from the American Type Culture Collection. The osteosarcoma cell
line KH-OS was provided by E. Gonos (Greek National Institute for
Research, Athens, Greece). The HT-29 colon cancer and NCI-H-460
lung cancer cell lines, as well as the glioblastoma cell line SF-268,
were provided by C. Dimas (Biomedical Research Foundation of the
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Academy of Athens). All cell cultures were grown at 37°C and 5%
CO2 in Dulbecco’s modified Eagle’s medium (Gibco, Grand Island,
NY) supplemented with 10% FBS (Gibco), 25 units/ml penicillin
(Sigma, St Louis, MO), and 25 pg/ml streptomycin (Invitrogen,
Grand Island, NY).
Construction of Representative Karyotypes
Logarithmically growing cell cultures were exposed to colcemid
(0.1μg/ml) (Gibco) for 1 to 3 hours, at 37°C in 5% CO2. Cells were
harvested by trypsinization (Gibco), suspended in medium, and spun
down (10minutes at 1000 rpm). Supernatant was removed completely,
and 5 ml of 0.075 M KCl (Sigma) at room temperature was added
drop by drop. The cells were incubated for 20 minutes at room
temperature, and then 1 ml of fixative [3× methanol (Applichem
GmbH, Darmstadt, Germany)/1× CH3COOH (Merck, Darmstadt,
Germany)] was added. Cells were spun down (10 minutes at 1000 rpm),
supernatant was removed, fixative was added, and the cells were re-
centrifuged for 10 minutes at 1000 rpm. Finally, cells were dropped
onto wet microscope slides and left to air-dry. For karyotypic analysis,
we combined inverted DAPI staining, G-banding, and molecular
karyotyping byM-FISH (MetaSystems GmbH, Altlussheim, Germany).
G-banding was performed after treatment with 0.25% trypsin (Gibco)
and Giemsa (Carl Roth GmbH, Karlsruhe, Germany) staining. M-FISH
was performed according to themanufacturer’s protocols (MetaSystems).
For inverted DAPI banding, slides were counterstained and mounted
with 0.1μg/ml DAPI in VECTASHIELD antifade medium (Vector
Laboratories, Burlingame, CA). Cytogenetic analyses were performed
using a ×63 magnification lens on a fluorescent Axio-Imager Z1, Zeiss
microscope, equipped with a MetaSystems charge-coupled device
camera and the MetaSystems Ikaros or Isis software. As representatives,
we considered the karyotypes of the major clone per cell harvest (at
least 25 metaphases stained with M-FISH and inverted DAPI band-
ing from one harvest were completely analyzed). Because of extreme
complexity of chromosomal rearrangements, karyotypes were written
in the extended form according to International System for Human
Cytogenetic Nomenclature (ISCN) 2009 [33,34].
Fluorescence In Situ Hybridization
For FISH, we used centromere-specific satellite DNA probes tar-
geting either all human centromeres or specific for chromosomes 1
[yellow, red + green signals; green, fluorescein isothiocyanate (FITC);
red, rhodamine], 9 (green, fluorescein), and 18 (green, FITC or purple/
blue, spectrum aqua). Probes were purchased from Vysis (Abbott Park,
IL) and Cytocell (Cambridge, United Kingdom). In brief, our protocol
was based on pepsin (Invitrogen) pretreatment, formamide (Appli-
chem) or NaOH (Sigma) target denaturation, overnight hybridization,
and high stringency post-hybridization washes. Telomeric peptide
nucleic acid (PNA) FISH was performed using a Cy3-(CCCTAA)3
PNA Probe according to the manufacturer’s instructions (Dako
Cytomation, Glostrup, Denmark). Briefly slides were incubated at
3.7% formaldehyde (Carlo Erba Reagenti SpA, Milano, Italy), washed
with 1× TBS (Dako Cytomation), immersed in pretreatment solution
(Dako Cytomation), and dehydrated with cold ethanol series (VWR,
Radnor, PA). Probe and target DNAwere denatured at 80°C for 5 min-
utes, and then slides were incubated for 1 hour at room temperature in
the dark. For M-FISH, we used the 24XCyte Kit from MetaSystems
GmbH. Staining was performed according to the manufacturer’s
instructions. All FISH preparations were mounted and counterstained
with VECTASHIELD antifade medium containing 0.1μg/ml DAPI
(Vector Laboratories). Digital images were captured and enhanced in
a MetaSystems workstation as described above.
Immunocytochemistry
Metaphase preparations were obtained through a modification of the
standard cytogenetic harvest technique that excluded acetic acid fixation.
Freshly fed and subconfluent cell cultures were incubated with colcemid
(0.01-0.04 mg/ml) for 0.5 to 16 hours at 37°C. Cells were dislodged
with trypsin-EDTA solution and centrifuged at 1000 rpm for 10 min-
utes, and the supernatant was discarded. Hypotonic solution (0.075 M
KCl, prewarmed to 37°C) was added to the cell pellet, gently mixed by
pipetting, and incubated for 20 to 30 minutes at 37°C. The cells were
washed with methanol. Preparations were cytospined for 10 minutes at
2000 rpm, and slides were left to air-dry and immediately placed to
4°C. Fluorescence immunocytochemistry was performed after phos-
phate-buffered saline (PBS) washes, permeabilization with Triton X-
100 (Applichem), and normal serum blocking. The CENP-A (Stressgen
Biotechnologies Corporation San Diego, CA) and CENP-C (Santa Cruz
Biotechnology, Santa Cruz, CA) antibodies were applied at dilutions
of 1:50 to 1:500 for 2 hours at room temperature. For antibody de-
tection, we used a suitable Alexa Fluor–conjugated secondary anti-
body (1:500-1:1000 in PBS; Molecular Probes, Grand Island, NY).
Slides were incubated for 1 hour and washed with PBS, and then FISH
was applied as described above. For antibody detection, we used
Alexa Fluor 568 (Molecular Probes)– and IgG-FITC (Santa Cruz
Biotechnology)–conjugated antibodies, respectively (1:500 in 1% BSA).
Chromatid Orientation FISH
Strand-specific telomeric CO-FISH was performed according to
Bailey et al. [35], with minor modifications. In brief, subconfluent cell
monolayers were cultured for 24 hours into medium containing 3 ×
10−3 mg/ml 5′-bromo-2’-deoxyuridine (Sigma). Colcemid (0.1μg/ml;
Gibco) was added for an hour before cell harvest. Metaphase spreads
were prepared by conventional cytogenetic methods. Chromosome
preparations were treated with 0.5 mg/ml RNase-A (Roche, Athens,
Greece) for 10 minutes at 37°C, stained with Hoechst 33258 (0.5μg/
ml; Sigma), incubated in 2× SSC (Invitrogen) for 15 minutes at room
temperature, and exposed to 365-nm UV light (Stratalinker 1800 UV
irradiator) for 30 minutes. The 5′-bromo-2’-deoxyuridine–substituted
DNA was digested with Exonuclease III (Promega, Madison, WI) in a
buffer supplied by the manufacturer (5 mM DTT, 5 mMMgCl2, and
50 mM Tris-HCl, pH 8.0) for 10 minutes at room temperature.
Digested strand denaturation was performed at 70°C, with 70% form-
amide (Applichem) in 2× SSC for 1 minute. The slides were then dehy-
drated through a cold ethanol series (70%, 85%, and 100%) and air-
dried. PNA-FISH was performed as above.
Statistical Analysis
One-way analysis of variance (ANOVA) or paired t tests were
performed using the MINITAB software.
Results
ALT Karyotypes Derive from Polyploidization Followed
by Frequent Chromosome Gains and Losses
The representative chromosome counts in metaphase spreads of the
10 cell lines of our panel varied from hypo-triploidy to near-heptaploidy
(according to ISCN 2009) [33]. High chromosome numbers, and
frequent karyotypic presence of two or multiple copies of specific clonal
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recombinant chromosomes, indicated that one, two, or more rounds
of genome reduplication have taken place and were selected to prevail
in the cell lines of this panel (Figures W1 and W2 and Supplementary
Data Set 1). In fact, all 10 karyotypes exhibited deviant modal chromo-
some numbers from those expected after complete dosage duplication or
multiplication of the whole normal human genome content. Consistent
with the hypothesis of Duesberg et al. [36,37], this discrepancy can be
explained by the increased susceptibility of polyploid cancer cells to
undergo chromosome losses. However, in the highly aberrant ALT
background, clonal chromosomal gains into the representative ploidy
index were equally frequent to clonal losses (79 vs 83, respectively). In
accordance to our recent report [38], all 10 cell lines of our panel exerted
a continuous propensity to generate subclones with reduplicated or
multiplied genomic material compared to their major clones. Typically,
the majority of observed polyploid metaphases were derivatives of
whole-genome duplication of a preexisting subclone that had the size
of the representative chromosome number (FigureW3). Hyperpolyploid
cells (i.e., mitotic nuclei that had undergone three or more rounds of
genome reduplication) were present but rare (<1%). These results in-
dicate that the ALT karyotypes examined in this study are clonal evolu-
tion products of an ongoing pressure for polyploidization that is
accompanied by equally frequent whole chromosome gains and losses.
Large Deletions, Terminal Structural Rearrangements,
and Whole-Genome Pericentromeric Recombinogenicity
Compared to telomerase-positive examples [39–42], the incidence
of clonal structural chromosome anomalies in the karyotypes of the
ALT cell lines of this panel was elevated by 3.7-fold (Figure 1A).
Although monoclonal in origin, all ALT cell lines displayed variable
percentages of co-existing cytogenetically distinct subpopulations,
characterized by unique clonal rearrangements (Figure W3). According
to ISCN 2009 [33], clonality of structural chromosome aberrations
in a cancer cell population is defined by the presence of an identical
marker chromosome, in at least two co-dividing cells. As representative,
we considered a particular karyotype of a series of at least 25 fully
analyzed mitotic cells from the same harvest, containing most, if not
all, of the identical chromosome markers shared by the majority of
the cells. In the representative karyotypes of the 9 unique ALT cell lines
of our panel, consisting of a total of 867 clonal autonomous chromo-
somes, 518 were identified as structurally aberrant (59.75%). Several
rearranged chromosomes were found in multiple copies or exerted
more than one structural anomaly (Figures W1–W3 and Supplemen-
tary Data Set 1). In a total of 649 identified unique clonal structural
aberrations, deletions of large genomic segments mostly spanning up
to chromosomal termini were the most frequent (41.4%), indicating
a robust pressure toward ALT chromosome trimming. More than half
of total deletions (65.7%) encompassed pericentromeric breakpoints.
Translocations between chromosomal segments composed the 30.1%
of total aberrations. They were mostly unbalanced and often complex
(involving more than two chromosomes). Consistent to our previous
work [24], a high proportion of the translocation breakpoints was
pericentromeric (52.8%). Clonal pseudo-dicentric or pseudo-polycentric
chromosomes were frequent (13.3%). Inverted duplications were
encountered in 4.8% of the total clonal rearrangements, whereas
Figure 1. Clonal structural chromosome rearrangements in human neoplastic cell lines: (A) Significant differences in the frequencies of
clonal structural aberrations in the karyotypes of eight ALT and eight telomerase-positive human cancer or transformed continuous cell
lines based on the results presented in this study and in [39–42] (ANOVA). (B) Frequencies of different types of aberrations in 649 unique
clonal chromosome rearrangements, identified by M-FISH and inverted DAPI banding in nine human ALT cell lines.
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isochromosome formations, inversions, or duplications were more rarely
detected (0.15%-1%; Figures 1B, W1, and W2). Hence, the increased
rates of telomere dysfunction operating in the ALT pathway lead pre-
dominantly to large-scale deletions and unbalanced translocations that
frequently occur at the pericentromeric regions.
Distribution of Telomere Dysfunction–Driven Clonal
Rearrangements along Chromosomal Termini and
Telomere Healing of Recombinant Chromosomes
From 1036 chromosome arms involved in ALT clonal structural
aberrations, 235 (22.7%) took part in terminal fusions. This percentage
is raised up to 39%, if we take into account the incidence of clonal
pseudo-polycentric chromosomes and inverted terminal duplications.
Interestingly, with the exception of chromosome 9, which showed
remarkably increased rates of telomeric recombinogenicity in both arms,
smaller chromosomes (13-22) showed a significantly higher propensity to
undergo clonal terminal p- or q-fusions (P = .031 by one-way ANOVA;
Figure 2A). In a highly proliferating cell population, clonal maintenance
of structurally rearranged chromosomes requires the presence and func-
tionality of the two main chromosomal organelles: the centromere and
the telomere [3,43]. ALT recombinant chromosomes may obtain telo-
meres by using a preexisting telomere of another chromosome (canonical
capping) or by introducing a tract of telomeric repeats through homolo-
gous recombination or NHEJ at a “blunt” chromosome end to heal it
(telomere capture or healing; Figure 2B) [21,44]. From 1036 arms of
the rearranged chromosomes described in this study, 54.9% were found
canonically capped. A substantial proportion (31.7%) of the recombinant
arms that were terminally protected by telomere healing acquired telo-
meres at pericentromeric regions (Figure 2C ). Expanding our earlier
observations [24], every human ALT centromere involved in peri-
centromeric whole-arm deletions was found capable to capture telomeres
and to become stabilized as a neo-acrocentric chromosome. Centro-
meres of chromosomes 18 to 20 were proved highly recombinogenic
in both telomeric and centromeric regions (Figure 2A). From 219 non-
centromeric breakpoints healed by telomere capture, 89 (40.6%) co-
incided with common CFSs, whereas 21.9% were found at genomic
regions bearing conserved interstitial telomeric repeats (ITRs; Fig-
ure 2D) [45]. These results indicate that in the ALT context, every
chromosome of the human karyotype can be involved in telomeric or
pericentromeric recombinogenicity and can acquire telomeric repeats at
broken ends.However, specific chromosomes display elevated propensity
for telomeric or centromeric instability. In addition, in a significant
proportion of structural rearrangements, clonality is entailed through
the acquisition of “neo-telomeres” near CFSs or conserved ITRs.
Clonal Pseudo-Polycentric Chromosomes and Recombinant
Chromosomes with Large ITRs
Compared to telomerase-positive examples, the ALT cell lines of this
panel demonstrated significantly higher frequencies of pseudo-dicentric
or pseudo-polycentric recombinant chromosomes as well as rearranged
chromosomes with cytologically visible blocks of telomeric repeats at
the recombination breakpoints (Figure 3, A and C). In humans, clon-
ality of polycentric recombinant chromosomes implies activity of one
centromere and inactivation of all other extra centromeres [46]. A
proportion of the rearranged chromosomes of our cell line panel was
interpreted as pseudo-dicentric by M-FISH and inverted DAPI band-
ing (Figures 3A, W1, and W2 and Supplementary Data Set 1). We
further investigated these peculiar entities of ALT genomic instability
Figure 2. Terminal fusions, pericentromeric rearrangements, and telomere healing: Virtually all chromosome arms of the human karyotype
are involved in ALT clonal end-to-end fusions, and all centromeres are capable of taking part in clonal translocations and of undergoing
telomere capture (p-arms of acrocentric chromosomes were not examined). (A) Chromosome 9 and the small chromosomes (18-22)
seemed more prone to take part in terminal or pericentric rearrangements (P < .01 by ANOVA). (B) A karyogram of the ALT U2-OS cell
line, stained by inverted DAPI banding and a telomere-specific PNA FISH probe, labeled with Cy3 (red), indicates chromosomal sites of
telomere healing (arrows). (C) Telomere healing in the ALT pathway occurs in a massive scale because 45.1% of the recombinant chromo-
some arms maintain clonality through capture of telomeric repeats. (D) Sites of frequent telomere capture.
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by centromere- and telomere-specific FISH and immunocytochemistry
using antibodies specific for CENP-A and CENP-C proteins. Fluores-
cent microscopy revealed that the excessive centromeres of clonal ALT
dicentric or polycentric chromosomes are indeed inactivated [47]
(Figure 3B). In addition, telomere-specific FISH showed that several
ALT clonal aberrant chromosomes deriving from end-to-end fusions
maintained cytologically visible blocks of telomeric repeats at recom-
bination sites (Figure 3D). Examination of the orientation of recom-
binant interstitial telomeric sequences, by strand-specific CO-FISH,
indicated that they represented NHEJ processes between telomeres at
an antiparallel orientation or between telomeres and non-telomeric
genomic sites. The above results demonstrate that in the ALT pathway
the inert tendency for aberrant large-scale epigenetic modifications is
not confined only at the telomeres [23,48] but may affect several
centromeric regions, facilitating inactivation of centromeres in excess,
in polycentric chromosomes produced by B/F/B cycles. In addi-
tion, increased terminal recombinogenicity generates recombinant
chromosomes with large ITRs.
Recurrent Chromosomal Rearrangements in the ALT Pathway
We then attempted to identify recurrent chromosome aberrations
that might be related to the genetic pathways driving ALT continuous
growth or may reflect specific patterns of ALT chromosome evolution
under increased telomeric instability. As recurrent, we considered all
unique chromosome anomalies, affecting the same chromosome, in
at least three of nine ALT cell lines. Losses of genomic material from
whole chromosome 13 were recurrently observed in seven of nine
karyotypes (77.7%). Other chromosomes found to be frequently lost
were 22 (77.7%), X (55.5%), 8, 14, and 18 (44.4%), as well as 1, 7, 9,
10, 11, 15, 16, and 21 (33.3%; Table W1). The same chromosomes
suffered also from large terminal or whole-arm deletions. Recurrent
chromosome gains beyond ploidy index involving chromosomes 2, 3,
5, and 20 were observed in 50% of the cases (Table W1). Recurrent
pericentromeric rearrangements are described in Table W2. Deletions
or unbalanced translocations of both arms of chromosome X were
observed in all the cell lines of this panel. The breakpoint that was
more frequently affected by terminal deletions was between Xq21.1
and Xq22.3 (in six of nine lines). A recombination/deletion hotspot
was localized at the short arm of chromosome 1 (between 1p32 and
1p36; observed in six of nine cell lines); in addition, chromosome 1
was also found to be affected by terminal deletions originating at 1q21
(four cases) with the other cases displaying either larger 1q deletions or
losses of the whole chromosome 1. Chromosome 2 exerted a recom-
bination hotspot at 2q31-2q36 (five of nine lines), whereas seven of
Figure 3. Distinctive cytogenetic findings of the ALT pathway: (A) Incidence of clonal pseudo-polycentric chromosomes in eight
telomerase-positive and eight ALT cell lines (P = .019 by ANOVA). Examples of two “cryptic,” clonal pseudo-dicentric recombinant
chromosomes of the ALT U2-OS karyotype: At the upper row, a neo-acrocentric derivative of chromosome 1, lacking the whole
1p arm, displays alphoid centromeric repeats specific for human centromeres 1 and 18, located in close proximity to the telomere
(M-FISH: yellow, specific for chromosome 1; purple, specific for chromosome 18; inverted DAPI: gray/black, ×630). At the lower
row, a complex rearrangement between chromosomes 1 and 9 maintains alphoid repeats from both centromeres 1 and 9. (B) Lack of
chromatid cohesion and negative staining for antibodies specific for CENP-A or CENP-C indicate that the terminally positioned centro-
mere 1 is inactivated, whereas centromere 9 remains active. (C) Frequencies of clonal rearranged chromosomes bearing cytologically
visible ITRs in a panel of eight telomerase-positive and eight ALT cell lines (P = .014 by ANOVA). (D) Strand-specific CO-FISH reveals
two types of clonal ITR: those representing NHEJ-mediated telomeric fusions between telomeres at antiparallel orientation (yellow
arrows) and fusions of telomeric repeats with non-telomeric genomic regions (white arrows; ×630).
1306 ALT Molecular Cytogenetics Sakellariou et al. Neoplasia Vol. 15, No. 11, 2013
nine ALT lines exerted increased rates of recombinogenicity for the
regions between 3q21 and 3q26. Chromosome 4 was found highly
recombinogenic at bands 4q21 to 4q23 (six of nine lines). Deletions
of the short arm of chromosome 5 were observed in six lines (66.6%).
A recombination hot region on this chromosome was identified between
5q31 and 5q35 (in six lines). Six of nine lines displayed rearrangements
into the regions 6q22.1 to 6q24.3, whereas four of them and two other
cell lines displayed a hot region between 6p21.3 and 6p23. Deletions
of the short arm of chromosome 8 were present in six of nine lines,
whereas five lines showed breakage at 8q21-8q24. The terminal regions
of chromosomes 7, 9, 11, and 18 to 21 showed a highly increased
tendency to undergo end-to-end fusions or terminal translocations
(88.8%). Pericentromeric rearrangements of chromosome 10 were
found in 88.8% of the ALT lines. A clustering of breakpoints was also
noted between bands 10q21.2 and 10q22.1. Six cell lines displayed
terminal deletions of 14q21-22. The pericentromeric region of chro-
mosome 16 exerted high rates of breakage and recombination, mainly
affecting p11.2 (in seven cell lines). Chromosome 18 showed also
remarkable pericentromeric recombinogenicity. Seven of nine cell lines
displayed large deletions of the short arm of chromosome 18, whereas
the other two lines showed full losses of the same chromosome. Similar
was the case with 18q. In addition to increased fragility that gave rise to
terminal deletions of either the short or the long arms, pericentromeric
regions of chromosome 18 were often taking part in translocations
with pericentric sites of other chromosomes such as 1, 7, 9, 10, 15,
16, 17, and 20. Losses of 19p were observed in six lines of our panel.
Figure 4. Structural chromosome instability before and after long-term reconstitution of telomerase activity in ALT cells: Reconstitution
of telomerase activity in ALT VA-13 cells significantly reduced overall genomic structural CIN in two independent harvests (a and b) of
the double-transfected isogenic VA-13TA cell line, grown in the presence of telomerase activity for more than 250 PDs. We analyzed
1095 VA-13 and 3416 VA-13TA chromosomes (1657 from harvest a and 1759 from b) using M-FISH/inverted DAPI. (A and B) Distribution
of random (non-clonal) structural rearrangements per chromosome, in the VA-13 cells, reveals that, in the ALT pathway, any chromosome
can be affected by increased recombinogenicity that predominantly affects terminal and pericentromeric regions and can be substantially
suppressed on long-term activation of telomerase. Random chromosome rearrangements were classified as telomeric, pericentromeric,
genomic (non-telomeric or centromeric), and unidentified. (C) Long-term expression of telomerase activity led to significant suppression of
telomeric and centromeric vulnerability (P < .0001 for VA-13TAa and for b, by paired t test). (D) The contribution of CFS in the proportion of
identified random chromosome breakpoints was not decreased, indicating that telomerase activation cannot repress ALT whole-genome
replication stress.
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Chromosome 20 showed increased propensity for pericentromeric
rearrangements and terminal fusions (88.8%). The long arm of
chromosome 21 showed recurrent propensity to undergo deletions or
translocations. A recombinatorial hotspot was found at 21q22.1. A
significant proportion (37.3%) of the above recurrent rearrangements
was localizing at common CFS (Tables W2 and W3), suggesting that
virtually all ALT chromosomes suffer from generalized replication
stress. Therefore, beyond extreme complexity, ALT karyotypes are
characterized by numerous recurrent chromosomal imbalances that
may uncover genes and biologic pathways related to ALT.
Reconstitution of Telomerase Activity in ALT Cells
Suppresses Terminal and Pericentromeric CIN
Reconstitution of telomerase activity in human ALT cells has been
related to decreased frequencies of telomere dysfunction and reduced
CIN [31]. The VA-13+hTERC+hTERT (VA-13TA) cells are stably
transfected to express telomerase activity for more than 250 population
doublings (PDs) and display high prevalence of near-pentaploidy
[31,38]. To address, in a cell-by-cell basis and in a chromosome band-
by-band basis, the extent of suppression of ALT-driven CIN between
co-dividing cells, we examined, before and after long-term restoration
of telomerase activity, the frequencies of non-clonal (unsystematic) struc-
tural rearrangements in 15 randomly selected metaphase spreads ob-
tained from the same harvest of the ALT VA-13 and 30 mitoses from
two independent harvests of the telomerase-positive VA-13TA stained
by M-FISH and inverted DAPI (Figures W3–W5). The VA-13TA
karyograms maintained, in duplicate, most of signature anomalies
observed in parental VA-13 cells (Figures W4 and W5). As expected
by the high rates of identified ALT clonal rearrangements, 238 of
1095 VA-13 chromosomes (21.7%) demonstrated random telomeric,
pericentromeric, or genomic recombinogenicity (Figure 4A). Reconstitu-
tion of telomerase activity resulted in a 2.3- to 3.6-fold decrease of this
phenotype (Figure 4B). Similar to the distribution of clonal anomalies,
random terminal or pericentromeric CIN affected all of the chromo-
somes of VA-13 and VA-13TA karyotypes (Figure 4A). Telomerase
activity significantly suppressed telomere fusions (4.6- up to 7.4-fold
decrease). Although frequent in both cell lines, unsystematic peri-
centromeric instability was also significantly repressed after restoration
of telomere dysfunction by ectopic telomerase expression (1.9- to
3.6-fold; Figure 4C). However, in both VA-13 and VA-13TA cell lines,
a significant proportion of identified random genomic rearrangements
coincided with common CFSs (16.2% in VA-13 and 20.5% to
28.6% for VA-13TAa and b, respectively; Figure 4D). These results
suggest that the breakpoint patterns of random ongoing chromosomal
instability in ALT cells are analogous to those of clonal rearrangements.
In addition, a proportion of the extremely high pericentromeric, but not
of CFS, recombinogenicity in the ALT karyotypes may be attributed to
mechanical forces generated during telomere dysfunction–driven B/F/B
cycles, because they are repressed by the introduction of telomerase [38].
Discussion
Tumor genome evolution in humans is considered a rather slow pro-
cess that may take several years to produce a highly malignant genome
[7,8,49,50]. Cellular immortalization and continuous culture growth
through the ALT pathway are accompanied by extremely high rates
of CIN that generate a plethora of random and clonal structural chro-
mosome anomalies [51]. Complicated more by high frequencies of
telomere dysfunction–driven polyploidization and extensive chromo-
some gains or losses [38,52], the ALT karyotype provides an ideal
context to study massive tumor genome alterations occurring in a
“fast-forward” mode.
In this first comparative detailed molecular cytogenetic analysis
of human ALT cancer and immortalized cell lines, we identified a
relatively large cohort of recombinant chromosomes suitable for sta-
tistical analyses concerning distribution of imbalances, breakpoints,
and clonality potential of cancerous rearrangements under extreme
telomere dysfunction.
Telomere dysfunction has been related to polyploidization through
genome endoreduplication as well as to chromosome losses through
B/F/B cycles and anaphase lagging [53,54]. Our results suggest that
extreme telomere deprotection might also be capable of triggering sin-
gle chromosomal non-disjunctions, or ALT immortalized cells may
gain chromosomes either by whole chromosome reduplication or
widespread hyperpolyploidy reduction [55].
Despite the increase of genomic content because of polyploidization,
the great extent of large-scale deletions and unbalanced translocations
identified in this study confirmed that the ALT genome suffers from
extensive dosage depletion of large segments of genomic material, as
described in a recent SNP array report from 22 human ALT cell lines
(including four of the lines of our panel: U-2OS, GM847, SaOS-2,
and VA13) [29]. The rarity of the ALT pathway in neoplasia and
the tightly regulated stochastic activation of ALT-like mechanisms in
embryonic stem (ES) and induced pluripotent stem (iPS) cells
[56,57] imply that a number of critical suppressor pathways are abro-
gated during massive engagement of ALT in cancer. Hence, several
ALT suppressors may exist and might be recurrently depleted in the
ALT cell lines of our panel.
We have shown in the past that, in addition to the expected fre-
quent telomeric vulnerability, ALT cells present also high rates of
pericentromeric instability [24]. Centromere mitotic recombination is
increased in cells lacking the DNA (cytosine-5) methyltransferase 3a
(DNMT3a) and DNMT3b [58], suggesting an altered state of ALT
centromeric heterochromatin that facilitates local recombination ac-
tivity. Our current data expand these previous observations, propos-
ing that, in the ALT context, every human telomere, or centromere,
can be involved in clonal rearrangements. Clustering of breakpoints
at specific genomic regions might correspond to peculiarities of local
chromosome architecture or represent selection-adaptation processes
favoring ALT critical genome alterations.
Although the presence of one or a few dysfunctional telomeres has
been associated with initiation of CIN [16], little is known about the
degree of involvement of every specific telomere of the human genome
in dysfunction-driven chromosome rearrangements. Our results reveal
that virtually all telomeres of the ALT human karyotype can be affected
by random or clonal recombinatorial events. However, specific chromo-
some termini were found more fusion-prone, and some were resistant.
This may suggest that specific human chromosome termini are more
vulnerable to generalized telomere protection failure than others. How-
ever, selection and adaptation of marker chromosomes that confer
oncogenic advantages to the ALT cells should not be disregarded. For
example, our results indicate high telomeric vulnerability of 9qter,
but this region contains important cancer-related genes such as Notch1,
TRAF2, and COBRA1 [59–61], depletion, duplication, or alteration of
which might be important for ALT.
To become clonal and to contribute into critical genome imbalances
that are responsible for cancerous growth, CIN-generated aberrant
chromosomes with blunt chromosome ends get stabilized through
extensive telomere healing [21,62]. In the absence of telomerase activ-
1308 ALT Molecular Cytogenetics Sakellariou et al. Neoplasia Vol. 15, No. 11, 2013
ity, clonal perpetuation of terminally deleted chromosomes implies
seeding of telomeres at the terminal breakpoint. Telomere healing
can be achieved through homologous recombination, NHEJ, or by
replication fork stalling and template switching [21]. We identified
219 genomic regions at which microscopically detectable terminal
deletions were mitotically stabilized by telomere healing so to become
clonally maintained. Virtually all pericentromeric regions were capable
to acquire telomeric repeats and to ensure mitotic perpetuation of
structurally altered chromosomes. CFSs and ITRs were also frequent
sites of telomere healing. Hence, our results demonstrate that, in the
ALT pathway, telomere healing occurs in a massive scale and may
involve both NHEJ and homologous recombination (HR).
Centromeric inactivation renders human meiotic or mitotic, recom-
binant, poly-centric chromosomes to become functionally mono-
centric by a largely unknown process of epigenetic modifications that
ameliorate binding of centromere-specific CENP proteins and restrict
chromatid cohesion that shapes primary constriction of metaphase
chromosomes despite the presence of alphoid DNA repeats [46].
The high frequencies of clonal pseudo-polycentric chromosomes in
the ALT pathway are described for the first time. They reflect the
well-established elevated rates of B/F/B cycles, owing to inert con-
tinuous stochastic telomere failure [22,53], but may also represent a
peculiar ALT heterochromatin epigenetic status that is highly per-
missive for the inactivation of excessive centromeres. Loss of function
of DNMT3a and DNMT3b in mice was associated with defects in
telomeric and subtelomeric heterochromatin structure, altered telomere
length homeostasis, and activation of ALT [63].
Along the clonal pseudo-polycentrics, recombinant chromosomes
with large ITRs, due to increased telomere recombinogenicity, may
also represent typical cytogenetic markers of the ALT karyotype.
Similar to variable in size, species-specific microscopically visible
ITRs, observed in hamsters, pigs, and muntjacs [64–66], ALT ITRs
remained relatively stable for several PDs and did not impair clonal
perpetuation of ITR-carrier chromosomes.
Oncogene-induced replication stress affects DNA integrity at
numerous CFSs within the cancer cell genome [11,67]. The great
extent of recombinogenicity at CFS, observed in the cell lines of our
panel, indicates that in ALT cells extreme replication stress affects the
whole genome. Another issue might be the implication of CFS genes in
ALT critical genomic rearrangements. Several CFS regions harbor genes
that may be involved in ALT, such as the CENPA-CAD, localized in
close proximity with FRAXB at Xq22.1 [68]. CENPA-CAD encodes
a complex recruited to centromeres to facilitate incorporation of
newly synthesized CENP-A that entails centromeric functionality
[69]. Deficiency of CENPA-CAD may explain the increased propen-
sity for the formation of ALT clonal pseudo-polycentric chromosomes
demonstrated in this study. Other important genes may also be affected
by recurrent losses of chromosome X, whole-arm deletions, or trans-
locations. For example, mutations in ATRX, sited at Xq21.1 (recurrently
affected in our study) have been considered capable to activate ALT
[29,68,70]. Interestingly, ATRX deficiency also disturbs sister chromatid
cohesion and causes mitotic aberrations [71].
Partial or full monosomies of the short arm of chromosome 1 have
been frequently reported in human malignant tumors that, in great
majority, express telomerase activity [72,73]. The ALT pathway seems
to take advantage of negatively unbalanced genome material from both
arms of this chromosome that is also proved highly recombinogenic
[[29] and this study]. However, chromosome 1qter might harbor
important genes for ALT, because its tip showed a remarkable re-
sistance to clonal telomere dysfunction. Indeed, EXO1 is located at
1q42-q43 [68]. EXO1 is important for generating both types of telo-
merase knockdown survivors (I and II) in budding yeast [74]. Terminal
deletions, affecting a large portion of 3q material including the hTERC
gene at 3q26.2, were identified in 55.5% of our ALT cell lines in-
cluding VA-13 and U2-OS. In study of Christodoulidou et al., we
verified the lack of hTERC expression in both VA-13 and U2-OS [38].
Four of nine ALT cell lines showed large terminal deletions involv-
ing 4q31. At least three genes that might associate with ALT con-
tinuous growth are located here: the transcriptional modulator of
cell growth and apoptosis SMAD1 [68,75]; SMARCA5, an SWItch/
sucrose non fermentable (SWI/SNF)-related matrix-associated actin-
dependent regulator of chromatin [68,76]; and the anaphase promoting
complex subunit 10 [68]. The TERT gene is located at the tip of the
short arm of chromosome 5 (p15.33) [68,77]. Interestingly, six of nine
cell lines showed variable size terminal deletions of 5p. The TERT gene
is silenced in all ALT cell lines of our panel [3,38,78–80].
The gene for the CENP-C binding protein, DAXX, is located at
6p21.3 [68]. DAXX has been shown to be a negative regulator of
ALT [29,81]. Consistent with Lovejoy et al., deletions or unbalanced
translocations of 6p21-22 were found in 55% of the ALT cell lines
of our panel (five of nine) [29]. In proximity to DAXX, at 6p22
[68], the DNA replication inhibitor Geminin (GMNN) resides, deple-
tion of which might be associated to increased rates of polyploidization
through whole-genome endoreduplication observed in ALT [[38,52]
and this study]. The same region (6p21.2) harbors RNF8 [68], an
E3 ubiquitin–protein ligase gene, involved in DDR. RNF8 mediates
the ubiquitination of histones H2A and H2AX, promoting the
formation of TP53BP1 and BRCA1 ionizing radiation–induced foci
[82]. The long arm of chromosome 6 displayed a recurrent break-
point hotspot at q21-q23.3. This region harbors ASF1, an H3/H4
chaperone that is required for the formation of senescence associated
heterochromatin foci, as well as the DNA replication licensing factor
MCM9 [83]. Recurrent deletions/translocations affecting 7q22.1-
7q22.3 were found in four of nine cell lines. This is the site for MLL5
gene, responsible for a histone methyltransferase that specifically mono-
methylates and dimethylates “Lys-4” of histone H3 (H3K4me1 and
H3K4me2) [68,84].
Losses of whole chromosome 8 and/or 8p arm deletions were
observed in seven of nine ALT cell lines. The WRN helicase gene
is located at 8p12 [68]. Despite its involvement in APBs, WRN is
dispensable for ALT [22]. Another gene that might be related to
the formation of ALT pseudo-polycentrics is the ESCO2, located
at 8p21.1, that is important for sister chromatid cohesion [68,85].
PIN2/TERF1 interacting, telomerase inhibitor 1 (PINX1) at 8p23.1 is a
microtubule-binding protein essential for faithful chromosome segrega-
tion [68,86]. PINX1mediates telomeric repeat binding factor 1 (TRF1)
and TERT accumulation in nucleoli and enhances TRF1 binding to
telomeres [87]. Tankyrase, a telomere interacting factor related to
mitotic fidelity and telomere integrity, is also located at 8p23.1 [68,88].
The telomeric region of 9p was involved in the structural rearrange-
ments in four of nine cell lines. The SMARCA gene that encodes
a protein participating in the large ATP-dependent chromatin re-
modeling complex SNF/SWI is located at 9p24.3 [68,89]. Dele-
tions and/or translocations affecting the short arm of chromosome 9
clustered between bands p21.2 and p21.3. This is the genomic site
for the tumor suppressor cyclin-dependent kinase inhibitor 2A
(p16) [68,90]. The cyclin-dependent kinase inhibitor 2A locus regu-
lates the two tumor-suppressive pathways (Rb and p53) that are
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most commonly disrupted in a wide range of human malignancies
[90,91]. The product of p16 induces cell cycle arrest by preventing
phosphorylation of pRb. Loss of function of p16 is reported to
be involved in immortalization as an alternative to inactivation of
pRb [91–93].
The tip of the short arm of chromosome 11 was involved in clonal
translocations or fusions in 66% of the nine lines. The HRAS onco-
gene is located in close proximity to 11pter [68]. This region harbors
also insulin-like growth factor 2 growth. It is an imprinted gene, ex-
pressed only from the paternal allele, and epigenetic changes at this
locus are associated with rhabdomyosarcomas [90,94,95]. The long
arm of chromosome 11 showed recurrent involvement in deletions
or translocations at bands q23.1 to q23.3; the MLL1 gene is located
here [68]. MLL1 is another histone methyltransferase implicated in
telomere metabolism [92]. MLL1 depletion in human diploid fibro-
blasts resulted in reduced levels of telomere H3/K4 methylation, the
induction of a DDR at telomeres, a p53-dependent growth arrest,
and cellular senescence [92].
Almost 50% of retinoblastomas use the ALT pathway to maintain
their telomeres [91]. The Rb1 gene localizes at 13q14.2 [68]. Recurrent
losses of whole chromosome 13 and/or deletions/translocations
involving 13q14.2 were evident in all cell lines of our panel. Fibro-
blast-deriving human ALT cell lines immortalized either sponta-
neously or by physical or chemical carcinogens, lack expression of
p16INK4a, and display hyperphosphorylation of pRb [91].
The region 15q13.1 was recurrently involved in translocations
affecting different chromosomes, such as 12, 18, and 20, and ter-
minal deletions. The NDNL2 gene that resides at 15q13.1 is a part
of the SMC5-SMC6 complex, involved in homologous recombination
DNA repair [68,93]. The complex is required for telomere main-
tenance through recombination in ALT cell lines. The same region
hosts the gene HERC2, responsible for an E3 ubiquitin–protein ligase
that regulates ubiquitin-dependent retention of DDR proteins on
damaged chromosomes [96].
The great majority of known ALT cell lines is impaired in the p53
pathway, either due to the expression of viral oncoproteins or through
a p53 mutation [97]. Immortalized cell lines, derived from Li-Fraumeni
breast fibroblasts carrying a germline mutation in p53, use ALT for telo-
mere maintenance [29,98]. Deletions and/or negatively unbalanced
translocations affecting the region of the TP53 gene at 17p13.1 were
observed in five of nine cell lines of our panel. In contrast, 17q might
harbor important genes for ALT because 17q was found to be unaffected
in eight of nine cell lines. The APB component BRCA1 is located at
17q21.31, RECQL5 at q25, MAP3K3 at q23.3, MAPKK6 at q24.3, as
well as the topoisomerase TOP2A located at q21.2 [68,99–103].
Gains of genomic material from 18p and pericentromeric rearrange-
ments of both the p- and q-arms of this chromosome were frequent in
the ALT cell lines of our study and might implicate genes such as trans-
forming growth factor β–induced factor homeobox 1 and methyltransferase-
like 4 at 18p11.3, whereas the 18q11.2 region harbors the BRCA1
modulator retinoblastoma binding protein 8 (RBBP-8) [68,104]. Several
genes located at 18p such as CENTRIN1, Yamaguchi sarcoma viral
oncogene homolog 1 (YES1), methyltransferase-like 4, transforming growth
factor β–induced factor homeobox 1, establishment of sister chromatid cohe-
sion N-acetyltransferase 1 (ESCO1), GATA-binding factor 6 (GATA6 ),
or cutaneous T-cell lymphoma-associated antigen 1 (CTAGE1) may confer
advantages to the ALT phenotype [68,103].
Losses of 19p and gains of 19q were observed in all lines of our
panel. The DNMT1 located at 19p13.2 may be an ALT repressor
[68]. DNA methylation is enriched at pericentromeric, centromeric,
and subtelomeric regions and is regarded to undergo late replication
and to prevent frequent recombination events [105]. The product of
the ZSCAN4 gene at the highly recombinogenic tip of 19q is responsible
for the stochastic engagement of an ALT-like phenotype in ES and iPS
cells [56,64].
Amplification of the long arm of chromosome 20 was observed in
44.4% of our cell line panel. The gene responsible for the immuno-
deficiency, centromeric region instability, and facial anomalies syn-
drome (ICF) syndrome, the DNMT3B, localizes at 20q11.21.
Hypomethylation of subtelomeric and epigenetic modifications at
telomeric regions was shown to affect the formation of telomere sister
chromatid exchange [106].TOP1 (20q12) and AURKA (20q13.2) may
also be candidates for the list with important genes for ALT continuous
growth [68,107,108].
The 21q22.1-3 was involved in structural aberrations in 50% of our
cell line panel. Specific genes, like RUNX1, ERG, TMPRSS2, and TFF,
located in this region have been involved in tumorigenesis [114].
Moreover, Pericentrin, a cell cycle regulation protein, necessary for
centrosomal function, is located at the tip of 21q (q22.3) [68,109].
Extensive loss of genomic material from chromosome 22 was verified
in six of nine lines. Chromosome 22 hosts, among many others, CHK2
(q12.1), Merlin (q12.2), and EP300 (q13.2) [68]. Mutations of the
CHK2 gene involved in DDR and the control of the cell cycle are
found in osteosarcomas [110]. Deletions in Merlin are responsible for
neurofibromatosis 2, associated with predisposition to the develop-
ment of the nerve sheath tumors schwannomas [111]. Interestingly,
telomerase activity could not be detected in all schwannomas examined,
implying that they might use ALT to sustain continuous growth [111].
The most consistent cytogenetic change reported in benign menin-
giomas is partial del(22)(q12) or total deletion of chromosome 22
[112]. Many meningiomas were found to use ALT [81]. Moreover,
cells without the p300 protein cannot effectively restrain growth and
division, allowing cancerous tumors to develop and grow [81].
In the highly aberrant ALT karyotypes, the identification of struc-
tural chromosomal rearrangements that might be harboring important
genes for the ALT pathway is hampered by stochastic events driven by
telomeric, pericentromeric, or CFS vulnerability. Notably, several of
the above recurrent breakpoints or imbalances correspond very well
to recently published SNP array data from 22 ALT cell lines (four of
those are included in our panel) [29]. Hence, despite the relatively
lower throughput and resolution, compared to whole-genome com-
parative genomic hybridization (CGH) approaches, spectral karyotyping
(SKY)/M-FISH/DAPI banding analysis is capable of identifying with
great accuracy major ALT imbalances and recurrent genomic recom-
binatorial hotspots.
Exogenous reconstitution of telomerase activity reduced significantly
the rates of B/F/B cycles and suppressed overall CIN in the ALT VA-13
cells [this study and [31,38]]. Telomeres, centromeres, and subtelo-
meric regions are considered to be highly sensitive to B/F/B-induced
double-strand breaks [113]. Our results show that a proportion of
ALT pericentromeric instability may be driven by mechanical forces
operating during B/F/B cycles. However, replication stress persists even
after stable restoration of telomerase activity, because the proportion
of random rearrangements affecting CFS in VA-13TA cells remained
similar or even increased compared to the isogenic ALT VA-13.
In contrast to many hematologic malignancies [114,115], and to a
small number of solid tumors [114,116], our results did not reveal clear
evidence for recurrent translocation-driven gene fusions in the ALT
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pathway. However, a thorough examination of specific breakpoints
such as those at 15q and 17q12 that were found consistently involved
in recurrent but variable translocations may—in the near future—
reveal if such entities exist.
Our data are consistent to previous studies [29,117] suggesting that
the major oncosuppressor pathway abrogated in ALT cells is p53/Rb/
INK4. In addition, the ALT cells take advantage of high rates of
endogenous CIN and undergo selection adaptation processes that
shape their genome toward the depletion of several regulators of the
epigenome such as ATRX and DAXX [29,117].
Hence, the ALT karyotype is shaped by massive stochastic chromo-
some mutation events that are selected to cluster in particular genomic
sites. In this context, clonality of cancerous recombinant chromosomes
is preserved through high rates of telomere seeding and frequent de-
activation of extra centromeres of fused chromosomes. Our results
shed light into the dynamics of clonal perpetuation of cancerous re-
combinant chromosomes under extreme telomere dysfunction, unveil-
ing, in parallel, specific genomic sites that may harbor genes critical for
ALT cancerous cell growth.
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